Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Posted on: Friday, 9 January 2009, 07:30 CST
A link to a live audio Webcast of the presentation may be accessed on the Endo Website at www.endo.com. The presentation will be archived for ninety days.
About Endo Pharmaceuticals
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals
Source: PR Newswire
Related Articles
- NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain
- Biovail Receives Canadian Approval for Ralivia(TM) for the Treatment of Moderately Severe Pain
- FDA Approves 10 MG ARICEPT(R) (Donepezil HCl Tablets) for Treatment of Severe Alzheimer's Disease
- U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for Treatment of Severe Ankylosing Spondylitis
- Colorado Becomes an International Center for Non-Fusion Treatment of Severe Spine Degeneration
- FDA Accepts Eisai's sNDA Application for ARICEPT(R) in the Treatment of Severe Alzheimer's Disease
- Eisai Resubmits sNDA Application for ARICEPT(R) for Treatment of Severe Alzheimer's Disease
- Eisai's sNDA Filing for ARICEPT(R) in the Treatment of Severe Alzheimer's Disease Not Accepted By FDA Due to Formatting Deficiencies
- Eisai Submits Application to FDA for ARICEPT(R) for Treatment of Severe Alzheimer's Disease
 |
 |
User Comments (0)
RSS Feeds